Welcome to
RBP World!
Drugs target to TLR3
| Drug name | Drug type | Disease/phenotype | Mechanism of action(MoA) | Phase | Status | Source |
|---|---|---|---|---|---|---|
| RINTATOLIMOD | Oligonucleotide | male breast carcinoma | Toll-like receptor 3 agonist | 1.0 | Completed | ClinicalTrials |
| RINTATOLIMOD | Oligonucleotide | HIV infection | Toll-like receptor 3 agonist | 1.0 | Completed | ClinicalTrials |
| RINTATOLIMOD | Oligonucleotide | pancreatic carcinoma | Toll-like receptor 3 agonist | 2.0 | Not yet recruiting | ClinicalTrials |
| RINTATOLIMOD | Oligonucleotide | breast carcinoma in situ | Toll-like receptor 3 agonist | 1.0 | Suspended | ClinicalTrials |
| RINTATOLIMOD | Oligonucleotide | fallopian tube cancer | Toll-like receptor 3 agonist | 1.0 | Terminated | ClinicalTrials |
| RINTATOLIMOD | Oligonucleotide | ovarian cancer | Toll-like receptor 3 agonist | 1.0 | Terminated | ClinicalTrials |
| RINTATOLIMOD | Oligonucleotide | ovarian cancer | Toll-like receptor 3 agonist | 1.0 | Recruiting | ClinicalTrials |
| BEVASIRANIB | Oligonucleotide | age-related macular degeneration | Toll-like receptor 3 activator | 3.0 | Withdrawn | ClinicalTrials |
| RINTATOLIMOD | Oligonucleotide | encephalomyelitis | Toll-like receptor 3 agonist | 3.0 | Completed | ClinicalTrials |
| RINTATOLIMOD | Oligonucleotide | chronic fatigue syndrome | Toll-like receptor 3 agonist | 3.0 | Completed | ClinicalTrials |
| BEVASIRANIB | Oligonucleotide | diabetic macular edema | Toll-like receptor 3 activator | 2.0 | Completed | ClinicalTrials |
| RINTATOLIMOD | Oligonucleotide | breast cancer | Toll-like receptor 3 agonist | 0.5 | Active, not recruiting | ClinicalTrials |
| RINTATOLIMOD | Oligonucleotide | COVID-19 | Toll-like receptor 3 agonist | 1.0 | Recruiting | ClinicalTrials |
| BEVASIRANIB | Oligonucleotide | macular degeneration | Toll-like receptor 3 activator | 2.0 | Completed | ClinicalTrials |
| BEVASIRANIB | Oligonucleotide | macular degeneration | Toll-like receptor 3 activator | 1.0 | Completed | ClinicalTrials |
| RINTATOLIMOD | Oligonucleotide | prostate adenocarcinoma | Toll-like receptor 3 agonist | 2.0 | Recruiting | ClinicalTrials |
| RINTATOLIMOD | Oligonucleotide | chronic fatigue syndrome | Toll-like receptor 3 agonist | 3.0 | Active, not recruiting | ClinicalTrials |
| BEVASIRANIB | Oligonucleotide | macular degeneration | Toll-like receptor 3 activator | 3.0 | Terminated | ClinicalTrials |
| RINTATOLIMOD | Oligonucleotide | melanoma | Toll-like receptor 3 agonist | 2.0 | Recruiting | ClinicalTrials |
| RINTATOLIMOD | Oligonucleotide | primary peritoneal carcinoma | Toll-like receptor 3 agonist | 1.0 | Terminated | ClinicalTrials |
| RINTATOLIMOD | Oligonucleotide | hematopoietic and lymphoid cell neoplasm | Toll-like receptor 3 agonist | 1.0 | Recruiting | ClinicalTrials |